ClinicalTrials.gg
Status unknownNCT04193982Updated Jan 26, 2021

An Investigator Initiated Prospective, Four Arms Randomized Comparative Study of Efficacy and Safety of Saroglitazar, Vitamin E and Life Style Modification in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)

A Phase 3 interventional study of Saroglitazar and Vitamin E in NAFLD, sponsored by Asian Institute of Gastroenterology, India. Status unknown at 1 site in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-01-26.

Sponsored by Asian Institute of Gastroenterology, India · Phase 3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing Vitamin E in Non-alcoholic Fatty Liver Disease — none open to participants now, 2 under way, none of them phase 3. Vitamin E · Non-alcoholic Fatty Liver Disease.

Planned enrollment
Largest of 17
250 · median 80
Started
2021
with 2 others
Phase 3
5 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
1 of 17
Asian Institute of Gastroenterology, India

Among the 17 studies testing Vitamin E in Non-alcoholic Fatty Liver Disease, this one has the largest planned enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 10th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 17 studies testing Vitamin E in Non-alcoholic Fatty Liver Disease is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

About Vitamin E

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Vitamin E in Non-alcoholic Fatty Liver Disease as a file.
02

Study summary

Saroglitazar and Vitamin E are both being extensively used in India for non alcoholic fatty liver disease, though none of these drugs are FDA approved for this indication.However they are backed up by number of studies which shows improvement in liver function , reduction in NAS score. However, there is no head to head trial , nor is there any study with a paired biopsy comparing two arms for a head to head study. We therefore designed this study to see the effect of Vitamin E vs Vitamin E plus saroglitazar vs Saroglitazar alone when compared to standard dietary and weight loss treatment for NAFLD with raised ALT levels.

03

Conditions studied

  • NAFLD

Keywords

  • Saraglitazar
  • Vitamin E
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Adults (age 18 to 60) 2. Confirmed Diagnosis of NAFLD established either by imaging (ultrasound, CT scan or MRI) or liver showing simple steatosis, within 6 months of the Screening Phase for this study. The diagnosis of NAFLD is made according to the American Association for the Study of Liver Diseases (AASLD) criteria (Chalasaniet al.2017).

      1. There is hepatic steatosis by imaging or histology,
      2. There is no significant alcohol consumption,
      3. There are no competing etiologies for hepatic steatosis
      4. There are no co-existing causes for chronic liver disease. 3. Patient's demonstration of understanding of study requirements and treatment procedures, willingness to comply with all protocol-required evaluations.

        1. Either take biopsy proven NAFLD or imaging based NAFLD with more than 1.5 times the . (being considered as 32) 5. Liver biopsy would be done in selected cases where the cause of transaminitis was uncertain of possible biopsy would be done on case to case basis.

Exclusion criteria

Exclusion Criteria:

  1. Absence of regular or excessive use of alcohol within 2 years prior to initial screening. History of alcohol will be taken from the patient and one or more family member and patient will be defined as non-alcoholic if he/she is a total abstainer or takes >20g (males) or 10g (females) of alcohol per day or greater than 14 drinks per week in males or greater than 7 drinks per week in females. Approximately 10 g of alcohol equals one 'drink' unit. One unit equals 30 ml of distilled spirits, 355 ml beer, or 120 ml glass of wine.
  2. Presence of alternative causes of fatty liver, including:

    • Weight loss >10% in the 6 months before the Screening Visit
    • Total parenteral nutrition, starvation or protein-calorie malnutrition
    • Use of drugs associated with NAFLD for more than 12 consecutive weeks in the 1 year before start of the study, including amiodarone, tamoxifen, methotrexate, systemic , anabolic steroids, tetracycline, estrogens in doses higher than used in oral , vitamin A, L asparaginase, valproate, chloroquine, or antiretroviral drugs.
  3. History of bowel surgery, gastrointestinal (bariatric) surgery or undergoing evaluation for bariatric surgery for obesity, extensive small-bowel resection, or orthotopic liver transplants (OLT) or listed for OLT.
  4. History of other chronic liver disease (Viral or C, hepatitis, cholestatic and metabolic liver diseases) and hemochromatosis.
  5. Patient has known cirrhosis (compensated /decompensated) either based on clinical criteria or liver histology or Imaging techniques.
  6. Patients with Hypothyroidism.
  7. Unstable cardiovascular disease, including:

    • unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the past 3 months), acute coronary syndrome within the past 6 months, acute myocardial infarction in the past 3 months or heart failure of class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the past 6 months
    • history of (within prior 3 months) or current unstable cardiac dysarrhythmias
    • uncontrolled hypertension (systolic BP>180 mmHg and/or diastolic BP >110 mmHg on two consecutive occasions)
    • stroke or within the prior 6 months
  8. History of myopathies or evidence of active muscle disease.
  9. History of in the past 5 years and/or active neoplasm with the exception of resolved superficial non-melanoma skin cancer.
  10. Participation in any other therapeutic clinical study in the past 3 months, including participation in any other NAFLD clinical trials.
  11. History of bladder disease and/or hematuria or has current hematuria except due to a urinary tract infection.
  12. Illicit substance abuse within the past 12 months.
  13. Pregnant/lactating female (including positive pregnancy test at the Screening Visit)
  14. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, , coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).
  15. Patients who will not comply with diet and lifestyle changes can be excluded from the final analysis.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Saraglitazar

    Patients will receive Saraglitazar 4 mg once daily for 6 months

    Drug: Saroglitazar

  • Experimental
    Vitamin E

    Patients will receive Vitamin E 400mg twice daily for 6 months

    Drug: Vitamin E

  • Experimental
    Combination

    Patients will receive combination of Saraglitazar 4 mg once daily and Vitamin E 400mg twice daily for 6 months

    Drug: Combination drug

  • Active comparator
    Lifestyle

    Patients will follow instruction from dietician and life style changes advise as per protocol including targeting 7 to 10percent weight loss in 6 months

    Behavioral: Lifestyle Changes

Interventions

  • Patient receives Saraglitazar 4mg once daily

  • Patient receive Vitamin E 400mg twice daily after food for 6 months

  • DrugCombination drug

    Patient receives Vitamine E 400mg twice daily and Saraglitazar 4 mg once daily for 6 months

  • BehavioralLifestyle Changes

    Patients receives dietary advise and does exercise in form of aerobic and targets 7 to 10 percent weight loss in 6 months

06

What researchers measure

Primary outcomes

  1. Change in Non alcoholic fatty liver fibrosis score at 8week, 16week and 24week.

    Non alcoholic fatty liver fibrosis score would be assessed . This is a non invasive test calculated by the formula : -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×109/l) - 0.66 × albumin (g/dl) Results are interpreted as : NAFLD Score \< -1.455 = F0-F2 NAFLD Score -1.455 - 0.675 = indeterminate score NAFLD Score \> 0.675 = F3-F4 Change in the NAFLD fibrosis score from the initiation of treatment and at end of 6 months would be assessed.

    Time frame: 6 months

Secondary outcomes

  1. Serum Alanine aminotransferase (ALT) changes at 6 months.

    Changes in Alanine aminotransferase at 6 months would be assessed.

    Time frame: 6 months

  2. Serum triglycerides (TG) level.

    Improvement as evidenced by decrease in triglyceride at 6 months.

    Time frame: 6 months

  3. Change in fibrosis on Liver Biopsy at 6 months.

    The study involves a paired liver biopsy and patients who undergo the second biopsy will be assessed for regression or decrease in fibrosis and steatosis score on biopsy. Score interpretation: Steatosis: \< 5%- 0, 5-33%- 1, \>33-66%- 2, \>66%- 3. Fibrosis: F0- No fibrosis, F1- Mild fibrosis, F2- Moderate fibrosis, F3- Severe fibrosis

    Time frame: 6 months

  4. Serum Aspartate aminotransferase (AST) level at 6 months.

    Changes in Aspartate aminotransferase at 6 months would be assessed.

    Time frame: 6 months

  5. Non alcoholic steatosis (NAS) score on liver biopsy at 6 months.

    Change in Non alcoholic Steatosis (NAS) score at 6 months. NAS score interpretation: Range- 0 to 8 ≥5- Non-alcoholic steatohepatitis (NASH)

    Time frame: 6 months

  6. Glycosylated Hemoglobin (HbA1C) Level at 6 months.

    Change in glycosylated hemoglobin level (amount of glucose attached to hemoglobin) from baseline and at 6 months.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Asian Institute of Gastroenterology Hospitals
    Hyderabad, Telangana 500089, India
    Recruiting
    • Mithun Sharma, MD · Contactdrmithunsharma@gmail.com · 8790622655
    • Padaki N Rao, MD DM · Sub investigator
    • Anand Kulkarni, MD DM · Sub investigator
    • Pramod DA, MD DM · Sub investigator
    • Nitin Jagtap, MD DNB · Sub investigator
    • Duvurr Nageshwar Reddy, MD DM · Sub investigator
    • Syeda Fatima Sultana, Pharm D · Sub investigator
08

References and documents

Publications

  • Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015 Mar;5(1):51-68. doi: 10.1016/j.jceh.2015.02.006. Epub 2015 Mar 6. PubMed 25941433 ↗
  • Dhiman RK, Duseja A, Chawla Y. Asians need different criteria for defining overweight and obesity. Arch Intern Med. 2005 May 9;165(9):1069-70. doi: 10.1001/archinte.165.9.1069-b. No abstract available. PubMed 15883250 ↗
  • Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012 Jun;142(7):1592-609. doi: 10.1053/j.gastro.2012.04.001. Epub 2012 May 15. No abstract available. Erratum In: Gastroenterology. 2012 Aug;143(2):503. PubMed 22656328 ↗
  • Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007 Mar;16(1):39-46. PubMed 17410287 ↗
  • Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011 Jul;54(1):344-53. doi: 10.1002/hep.24376. PubMed 21520200 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2021; primary completion for Sep 2021, 7 months later.

Of 34 phase 3 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 61. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2019
First posted
Dec 11, 2019
StartEst.
Jan 31, 2021
Primary completionEst.
Sep 30, 2021
CompletionEst.
Oct 31, 2021
Last update
Jan 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04193982
Responsible party
Sponsor
First posted
Dec 11, 2019
Start date
Jan 31, 2021 (estimated)
Primary completion
Sep 30, 2021 (estimated)
Completion
Oct 31, 2021 (estimated)
Last update
Jan 26, 2021

Study contacts

Mithun Sharma, MD
Contact
drmithunsharma@gmail.com
8790622655

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saroglitazar · Vitamin E

Start the discussion